Mesoblast Ltd (MESO) stock
MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
$11.64−0.27 (-2.27%)
Close on Nov 18, 2026Market cap $1.51BP/E –Yield –
Mesoblast revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Mesoblast's revenue for the twelve months ending Jun 30, 2023 was $7.50M, down 26.5% year over year. For fiscal 2026 it was $120.25M, up 599.2% from the year before. Over ten years it grew 10.9% a year on average. The highest annual figure on record is $120.25M in fiscal 2026.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $120.25M | +599.2% |
| FY2025 | Jun 30, 2025 | $17.20M | +191.4% |
| FY2024 | Jun 30, 2024 | $5.90M | -21.3% |
| FY2023 | Jun 30, 2023 | $7.50M | -26.5% |
| FY2022 | Jun 30, 2022 | $10.21M | +37.4% |
| FY2021 | Jun 30, 2021 | $7.43M | -76.9% |
| FY2020 | Jun 30, 2020 | $32.16M | +92.3% |
| FY2019 | Jun 30, 2019 | $16.72M | -3.6% |
| FY2018 | Jun 30, 2018 | $17.34M | +618.9% |
| FY2017 | Jun 30, 2017 | $2.41M | -94.3% |
| FY2016 | Jun 30, 2016 | $42.55M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $2.14M | -3.8% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $1.94M | -3.6% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $2.13M | -10.4% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $1.50M | -58.2% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $2.22M | +12.7% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $2.01M | +5.0% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $2.38M | +6.3% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $3.59M | +175.4% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $1.97M | +181.5% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $1.92M | -84.3% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $2.24M | +1.6% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $1.31M | -92.3% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $701.00K | -64.4% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $12.20M | +876.9% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $2.21M | +18.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $17.05M | +46.5% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $1.97M | +15.7% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $1.25M | +16.7% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $1.87M | -86.0% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $11.64M | – |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $1.70M | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $1.07M | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $13.40M | – |
See a number that looks wrong?